N-hydroxy-N-[5-(phenylthio)thien-2-yl]methyl urea

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-hydroxy-N-[5-(phenylthio)thien-2-yl]methyl urea
• 英文别名: 1-Hydroxy-1-(5-phenylthiothien-2-ylmethyl)urea；1-hydroxy-1-[(5-phenylsulfanylthiophen-2-yl)methyl]urea
• 化学式: C₁₂H₁₂N₂O₂S₂
• 分子量: 280.371
• InChiKey: BNPJHCGWAGKRCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-Phenylsulfanyl-thiophene-2-carbaldehyde oxime 在 盐酸 、 吡啶硼烷 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 2.17h， 生成 N-hydroxy-N-[5-(phenylthio)thien-2-yl]methyl urea
  参考文献：
  名称：

  Structure−Activity Relationships of N-Hydroxyurea 5-Lipoxygenase Inhibitors

  摘要：

  The discovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the development of a broad structure-activity relationship (SAR) study. This study identified requirements for improving potency and also extending duration by limiting metabolism. Potency could be maintained by the incorporation of heterocyclic templates substituted with selected lipophilic substituents. Duration of inhibition after oral administration was optimized by identification of structural features in the proximity of the N-hydroxyurea which correlated to low in vitro glucuronidation rates. Furthermore, the rate of in vitro glucuronidation was shown to be stereoselective for certain analogs. (R)-N-[3-[5-(4-Fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hy- droxyurea (17c) was identified and selected for clinical development.

  DOI：

  10.1021/jm9700474

文献信息

• Urea based lipoxygenase inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05185363A1

  公开（公告）日：1993-02-09

  Substituted phenyl, naphthyl, and thienyl N-hydroxy urea compounds form a class of potent inhibitors of 5- and 12-lipoxygenase and are thus useful compounds in the treatment of inflammatory disease states where leukotrienes and other products of lipoxygenase enzyme activity are implicated.

  苯基、萘基和噻吩基N-羟基脲化合物形成了一类强效的5-和12-脂氧化酶抑制剂，因此在治疗炎症性疾病状态中，其中白三烯和其他脂氧化酶酶活性产物起作用，这些化合物是有用的。
• Pharmaceutical compounds
  申请人：Lilly Industries limited

  公开号：US05158971A1

  公开（公告）日：1992-10-27

  A pharmaceutical compound of the formula ##STR1## in which R.sup.1 is halo-C.sub.1-10 alkyl, C.sub.1-10 alkylthio, halo-C.sub.1-10 alkylthio or optionally substituted phenylthio, R.sup.2 is hydrogen or C.sub.1-4 alkyl, R.sup.3 and R.sup.4 are each hydrogen or C.sub.1-4 alkyl, and X is oxygen or sulphur; and salts thereof.

  一种药物化合物的化学式为##STR1## 其中R.sup.1是卤代C.sub.1-10烷基，C.sub.1-10烷基硫，卤代C.sub.1-10烷基硫或可选取代苯基硫，R.sup.2是氢或C.sub.1-4烷基，R.sup.3和R.sup.4分别是氢或C.sub.1-4烷基，X是氧或硫;以及其盐。
• Thien-2-yl methylurea derivatives as leukotriene inhibitors
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0459748A2

  公开（公告）日：1991-12-04

  A pharmaceutical compound of the formula in which R¹ is halo-C₁₋₁₀ alkyl, C₁₋₁₀ alkylthio, halo-C₁₋₁₀ alkylthio or optionally substituted phenylthio, R² is hydrogen or C₁₋₄ alkyl, R³ and R⁴ are each hydrogen or C₁₋₄ alkyl, and X is oxygen or sulphur; and salts thereof.

  一种药物化合物，其化学式为 其中 R¹ 是卤代-₁₋₁₀ 烷基、C₁₋₁₀ 烷硫基、卤代-₁₋₁₀ 烷硫基或任选取代的苯硫基、R² 是氢或 C₁₋₄ 烷基，R³ 和 R⁴ 分别是氢或 C₁₋₄ 烷基，X 是氧或硫；及其盐类。
• UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS
  申请人：ABBOTT LABORATORIES

  公开号：EP0588785A1

  公开（公告）日：1994-03-30
• EP0588785A4
  申请人：——

  公开号：EP0588785A4

  公开（公告）日：1991-12-30